Ten years' real-life experience on the use of multikinase inhibitors in patients with advanced differentiated thyroid cancer.

Fernando JerkovichSoledad CapalboErika Abelleira Fabián Pitoia

Published in: Endocrine (2024)

TKIs demonstrated efficacy and tolerability comparable to real-world data in RR-DTC. PFS was not statistically different between sorafenib and lenvatinib. Our study will help guide physicians in making informed decisions regarding treatment sequencing with TKIs in these patients.

Keyphrases

end stage renal disease
ejection fraction
newly diagnosed
primary care
chronic kidney disease
single cell
electronic health record
big data
machine learning
double blind
patient reported